Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

Biologic Therapies for NHL (Excluding Pre-clinical Models) Poster II

Sunday, December 7, 2008: 6:00 PM-8:00 PM
Hall A (Moscone Center)
Two-Monthly Rituximab Infusions Maintain Target Concentrations: Pharmacokinetic Data of the AGMT-NHL9 Maintenance Study in Patients with Follicular Lymphoma in Complete or Partial Remission

Ulrich Jaeger, MD1, Otto Krieger, MD2*, Georg Hopfinger, MD3*, Cathrin Skrabs, MD1*, Christine Einberger1*, Veronika Huter, MD4*, Hubert Hausmaninger, MD5*, Johannes Drach, MD6, Markus Raderer, MD6*, Michael Woo, Pharm, D7*, Helen Melzer, PhD1*, Richard Greil, MD5* and Michael A Fridrik, MD8

1Division of Hematology and Hemostaseology, Department of Medicine I, Vienna, Austria
2Department of Internal Medicine I, Hospital Elisabethinen, Linz, Austria
3Department of Medicine III, Hanusch Hospital, Vienna, Austria
4Roche Austria, Vienna, Austria
5Department of Medicine III, Salzburg, Austria
6Division of Oncology, Department of Medicine I, Vienna, Austria
7Clinical Pharmacology Dept., Hoffmann-La Roche Inc., Nutley, NJ
8Internal Medicine 3, Center of Hematology and Medical Oncology, Linz, Austria

Safety in Patients Receiving Maintenance Rituximab for Follicular Lymphoma: Results from Phase IIIb MAXIMA Trial

Mathias Witzens-Harig1*, Joachim Hipp2*, Anthony D. Ho3*, Nikolai Nikolov2*, Daniel Thurley2*, Manfred Hensel, MD4, Stefan Oertel2* and Michael Wenger2*

1Med. Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany
2Roche, Basel
3Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany
4Mannheimer Onkologie Praxis, Mannheim, Germany

Alemtuzumab-CHOP for Aggressive T Cell Lymphoma. A Phase II HOVON 69 TrialClinically Relevant Abstract

J.C. Kluin-Nelemans, MD, PhD1, Marinus Van Marwijk Kooij, MD, PhD2, P.J. Lugtenburg, MD, PhD3, Pierre W Wijermans4, Willem JL Van Putten, MSc3* and Gustaaf W van Imhoff, MD, PhD5

1Hematology, University Medical Centre Groningen, Groningen, Netherlands
2Sophia Hospital, Zwolle, Netherlands
3Dept. of Hematology, Erasmus MC, Rotterdam, Netherlands
4Hospital Leyenburg, The Hague, Netherlands
5Hematology, Groningen University Medical Center, Groningen, Netherlands

Effect of Prior Rituximab on Residence Time of I131 Tositumomab Consolidation Therapy in Patients (pts) with Non Hodgkin's Lymphoma (NHL): Analysis of SWOG Clinical TrialsClinically Relevant Abstract

Julia Schaefer-Cutillo1*, Vaseem Chengazi1*, Derick R Peterson1*, David G. Maloney2, Kevin Kibler1*, Erin Cebula1*, Steven Bernstein1, Faith Young1*, Oliver W. Press2, Lisa M. Rimsza3, Richard I. Fisher1* and Jonathan W. Friedberg, MD1

1James P. Wilmot Cancer Center, University of Rochester, Rochester, NY
2Fred Hutchinson Cancer Rsch. Ctr., Seattle
3University of Arizona

Phase II Study of Short Course CHOP-Rituximab Followed by 90-Y Ibritumomab Tiuxetan as First-Line Treatment for Follicular Lymphoma: An Update and Extension of Preliminary Findings on Predictors of Relapse

Rachel C. Jankowitz, MD1, Kenneth A. Foon, MD2, The Minh Luong, M., Sc3*, Stephanie R. Land, PhD4*, Nicholas A. DeMonaco, MD5, Steven H. Swerdlow, MD6, Judith Joyce, MD7*, Jennifer Osborn, MD8*, Terry Evans, MD9 and Samuel A. Jacobs, MD1

1Department of Medicine, Division Hematology/Oncology, University of Pittsburgh, Pittsburgh, PA
2Nevada Cancer Institute, Las Vegas, NV
3Biostatistic Facility, University of Pittsburgh Cancer Institute, Pittsburgh, PA
4Department of Public Health, NSABP and University of Pittsburgh Cancer Institute, Pittsburgh, PA
5Oncology-Hematology Associates, PA, Clinton, MD
6Department of Pathology, University of Pittsburgh School of medicine, Pittsburgh, PA
7Department of Radiology, University of Pittsburgh Medical Center, Pittsburgh, PA
8UPMC Cancer Center at UPMC Passavant, UPMC Cancer Center, Pittsburgh, PA
9UPMC Cancer Center - Arnold Palmer Pavilion, University of Pittsburgh Medical Center, Greensburg, PA

Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s LymphomaClinically Relevant Abstract

Franck Morschhauser1*, Angelika Bischof-Delaloye2*, Ama Z S Rohatiner, MD3, Gilles Andre Salles, MD, PhD4, Jens Kuhlmann5*, Willem JL Van Putten6*, John Radford7*, Pierre Soubeyran8, Achiel Van Hoof9 and Anton Hagenbeek10*

1Hematology, Centre Hospitalier Universitaire, Lille, France
2Médecine nucléaire (NUC), Centre Hospitalier Universitaire Vaudois Lausanne, Lausanne, Switzerland
3St Bartholomew's Hospital, London, United Kingdom
4Hematologie, Centre Hospitalier Lyon-Sud, Pierre-Benite, France
5Bayer Schering Pharma AG, Berlin, Germany
6Dept. of Hematology, Erasmus MC, Rotterdam, Netherlands
7Christie Hospital and The University of Manchester, Manchester, United Kingdom
8Institut Bergonié & Université Victor Segalen, Bordeaux, France
9A. Z. Sint Jan AV, Brugge, Belgium
10Universitair Medisch Centrum Utrecht, NL-3584 CX Utrecht, Netherlands

Comparing Standard IPI with Revised-IPI in Patients with Diffuse Large B-Cell Lymphoma: Which Has a More Differential Potential for Predicting the Outcomes after R-CHOP Chemotherapy

Deok-Hwan Yang1*, Jae Sook Ahn1*, Yeo-Kyeoung Kim2, Je-Jung Lee2*, Young Jin Choi3*, Ho Jin Shin3*, Joo-Seop Chung3*, Joon Ho Moon4*, Yee Soo Chae4*, Jong Gwang Kim4*, Sang Kyun Sohn5 and Hyeoung-Joon Kim2*

1Hematology-Oncolology, Chonnam National University Hwasun Hospital, Jeollanam-do, South Korea
2Hematology-Oncology, Chonnam National University Medical School, Jeollanam-do, South Korea
3Internal Medicine, Pusan National University School of Medicine, Busan
4Hematology/Oncology, Kyungpook National University Hospital, Daegu, South Korea
5The Korean Society of Hematology, Seoul, South Korea

A Phase II Trial of Combination Bortezomib (Velcade®) and Rituximab for Untreated “High Tumor Burden” Indolent Non-Hodgkin Lymphoma (NHL)Clinically Relevant Abstract

Kevin A. David, MD1*, Mitchell R. Smith, MD, PhD2, Izidore S. Lossos, MD3, Eren Roubal, BS1*, Jane N. Winter, MD1*, Steve T. Rosen, MD1*, Leo I. Gordon, MD1* and Andrew M. Evens, DO, MS1*

1Hematology/Oncology, The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
2Fox Chase Cancer Center, Philadelphia, PA
3Department of Medicine, Division of Hematology, University of Miami, Miami, FL

Phase I Results of Combination Gemcitabine and Bortezomib (Velcade®) for Relapsed/Refractory Nodal T-Cell Non-Hodgkin Lymphoma (T-NHL) and Aggressive B-Cell NHL (B-NHL)

Andrew M. Evens, DO, MS1, Leo I. Gordon, MD1*, David Patton, BS1*, Steven T. Rosen, MD1*, Jane N. Winter, MD1*, Justin Kline, MD2*, Koen Van Besien, MD2* and Sonali M. Smith, MD2

1Hematology/Oncology, The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
2University of Chicago, Chicago, IL

Prognostic Value of Early 18fluorodeoxyglucose PET Scan in Patients with Diffuse Large B Cell Lymphoma Treated with Rituximab Plus CHOP or High-Dose CHOPClinically Relevant Abstract

Jehan Dupuis1*, Emmanuel Itti2*, Christophe Fruchart3*, Stéphane Bardet4*, Alain Rahmouni5*, Jean-Pierre Vilque3*, Chieh Lin2*, Karim Belhadj1*, Taoufik El Gnaoui1*, Frédérique Kuhnowski1*, Michel Meignan2* and Corinne Haioun1

1Service d'Hématologie Clinique, Hôpital Henri Mondor, Créteil, France
2Biophysique & Médecine Nucléaire, Hôpital Henri Mondor, Créteil, France
3Service D'hématologie, Centre françois Baclesse, Caen, France
4Service De Médecine Nucléaire, Centre François Baclesse, Caen, France
5Service D'Imagerie Médicale, Hôpital Henri Mondor, Créteil, France

First-Line Treatment with Rituximab Combined with Intravenous or Oral Fludarabine for Patients with Extranodal Mucosa Associated Lymphoid Tissue (MALT) LymphomaClinically Relevant Abstract

Antonio Salar, MD, PhD1*, Eva Domingo-Domènech, MD2*, Cristina Estany, MD3*, Miguel Canales, MD, PhD4, Octavio Servitge, MD2*, Fernando Gallardo, MD, PhD5*, Guadalupe Fraile6* and Carlos Montalbán, PHD6*

1Hematology Department, Hospital del Mar, Barcelona, Spain
2Hematology, Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Spain
3Hematology, Hospital Mutua de Terrasa
4Hospital Universitario La Paz, Madrid
5Dermatology, Hospital del Mar, Barcelona, Spain
6Internal Medicine, Hospital Ramon y Cajal

A Cumulative Series from 14 Western Countries Suggests That Rituximab Significantly Changed the Dismal Natural History of Intravascular Large B-Cell Lymphoma (IVL) 

Andres JM Ferreri, MD1, Silvia Govi, M.D.1*, Giuseppina Patrizia Dognini, M.D.2*, Maria Bouzani, M.D.3*, Claudia Ruth Bollinguer, M.D.4*, Michel D'Incan, M.D.5*, Emmanuel Delaporte, M.D.6*, Mehdi Hamadani, M.D.7*, Fabrice Jardin, M.D.8*, Magdalena Martusewicz-Boros, M.D.9*, Mauro Montanari, M.D.10*, Arpad Szomor, M.D.11*, Roberto Crocchiolo, M.D.1*, Emanuele Zucca, M.D.12*, Franco Cavalli, M.D.12* and Maurilio Ponzoni, M.D.13*

1Unit of Lymphoid Malignancies, Department of Oncology, Istituto Scientifico San Raffaele, Milano, Italy
2Medicina I, Azienda Ospedaliera Treviglio-Caravaggio, Treviglio, Italy
3Evangelismos Hospital, Athens, Greece
4University Hospital of Essen, Essen, Germany
5CHU-Hotel-Dieu, Clermont-Ferrand, France
6CHU-Lille, Lille, France
7Division of Hematology/Oncology, Ohio State University, Columbus, OH
8Hematology, INSERM U918, Centre Henri Becquerel, Rouen, France
9National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland
10Azienda Ospedali Riuniti di Ancona, Ancona, Italy
11Medicine Department University of Pecs, Pecs, Hungary
12Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
13Unit of Lymphoid Malignancies, Pathology Unit, Istituto Scientifico San Raffaele, Milano, Italy

Front-Line Chemo-Immunotherapy Rituximab-FC + Rituximab Maintenance in Patients with Untreated Advanced Stage Non Follicular Lymphoma (INFL): Preliminary Results of a Prospective Study of the Intergruppo Italiano Linfomi and Roche (ML18324)Clinically Relevant Abstract

Luca Baldini1*, Alessandro Pulsoni2*, Giuseppe Rossi3*, Umberto Vitolo4*, Enrica Morra5*, Barbara Olivero6*, Elena Cavalieri2*, Francesco Merli7*, Luigi Rigacci8*, Francesco Nobile9*, Lorella Orsucci10*, Maura Brugiatelli11*, Pellegrino Musto12*, Giorgio Lambertenghi Deliliers1 and Enrica Gamba13*

1UO Ematologia 1-CTMO, Fondazione Policlinico MaRe, IRCCS, Universita' degli Studi, Milano, Italy
2Dipartimento Biotecnologie Cellulari ed Ematologia, Universita' La Sapienza, Roma, Italy
3Department of Hematology, Spedali Civili, Brescia, Italy
4Azienda Ospedaliera San Giovanni Battista, Division of Hematology, Torino
5Divisione Ematologia, Ospedale Niguarda, Milano, Italy
6UO Ematologia 1-CTMO, Fondazione Policlinico MaRe IRCCS, Milano, Italy
7Hematology, Ospedale Reggio Emilia, Reggio Emilia, Italy
8Hematology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
9Hematology Unit, Azienda Ospedaliera " Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
10On the behalf of GIMURELL, Hematology 2, AOU San Giovanni Battista, Turin, Italy
11Ematologia, Ospedale Messina
12Ematologia e Trapianto Cellule Staminali, IRCCS, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture (PZ), Italy
13Roche-Monza, Italy

Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/LymphomaClinically Relevant Abstract

Kamal Sharma, DO1, John E. Janik, MD1*, Deirdre O'Mahony, MD1*, Donn Stewart, MD1*, Stefania Pittaluga, MD2*, Maryalice Stetler-Stevenson, MD, PhD2*, Elaine S. Jaffe, MD2*, Mark Raffeld, MD2*, Thomas A. Fleisher, MD3*, Cathryn C. Lee, NP1*, Nicole Urquhart, MD4*, Seth Steinberg, PhD5*, Thomas A. Waldmann, MD1* and John C. Morris, MD1*

1Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
2Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
3Department of Laboratory Medicine, Center for Cancer Research, National Institutes of Health, Bethesda, MD
4Department of Pathology, ATL Treatment Project, University of West Indies, Mona, Jamaica
5Biostatistics and Data Management Section, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

Comparative Outcomes Following CP-R, CVP-R and CHOP-R in Patients with Waldenstrom’s Macroglobulinemia

Leukothea Ioakimidis, PhD1*, Christopher Patterson, MD2*, Jacob Soumerai3*, Robert Manning1*, Patricia Sheehy, NP1* and Steven Treon, MD, PhD4

1Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Dana Farber Cancer Institute, Boston, MA
3Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
4Dana-Farber Cancer Institute, Boston, MA

*signifies non-member of ASH